Amicus Therapeutics, Inc. (FOLD)
Stock Price:
$18.26 USD
-0.67 (-3.54%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $18.76 +0.50 (2.74%) Oct 28, 7:38 PM
Key Info
| Market Cap |
4.73B |
| Revenue (ttm) |
226.94M |
| Net Income (ttm) |
-292.98M |
| Shares Out |
258.79M |
| EPS (ttm) |
-1.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$18.26 |
| Previous Close |
$18.93 |
| Change ($) |
-0.67 |
| Change (%) |
-3.54% |
| Day's Open |
18.58 |
| Day's Range |
17.96 - 18.59 |
| Day's Volume |
1,299,627 |
| 52-Week Range |
6.25 - 19.46 |
More Stats
| Market Cap |
4.73B |
| Enterprise Value |
4.62B |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
258.79M |
| Float |
253.61M |
| EPS (basic) |
-1.14 |
| EPS (diluted) |
-1.14 |
| FCF / Share |
-1.05 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
29.83M |
| Short Ratio |
14.72 |
| Short % of Float |
11.76% |
| Beta |
1.17 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
20.82 |
| PB Ratio |
12.92 |
| Revenue |
226.94M |
| Operating Income |
-272.65M |
| Net Income |
-292.98M |
| Free Cash Flow |
-271.62M |
| Net Cash |
107.37M |
| Net Cash / Share |
0.41 |
| Gross Margin |
70.62% |
| Operating Margin |
-120.14% |
| Profit Margin |
-129.10% |
| FCF Margin |
-119.69% |
| ROA |
-21.04% |
| ROE |
-60.97% |
| ROIC |
-50.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (11)
| Buy |
9 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.09*
(10.02% upside)
Low
12.0
Current: $18.26
High
31.0
Target: 20.09
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 182 | 91.25 | 36.93 | 4.96 | - | 1.22 | 0.36 | 18.41 | 21.43 | 0.92 |
| Revenue Growth | 99.72% | 147.08% | 644.86% | - | - | 237.19% | -98.03% | -14.1% | 2224.73% | - |
| Gross Profit | 160 | 76.84 | 30.69 | 4.13 | - | 1.22 | 0.36 | 18.41 | 21.43 | 0.92 |
| Operating Income | -301 | -325 | -676 | -175 | -126 | -68.60 | -64.18 | -52.93 | -50.89 | -55.84 |
| Net Income | -356 | -349 | -284 | -200 | -132 | -68.93 | -59.63 | -48.79 | -44.41 | -54.94 |
| Shares Outstanding | 240 | 186 | 153 | 134 | 110 | 74.44 | 51.29 | 45.57 | 34.57 | 27.73 |
| Earnings Per Share | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | 1.16 | 1.07 | -1.28 | -1.98 |
| EPS Growth | - | - | - | - | - | - | 8.41% | - | - | - |
| Operating Cash Flow | -250 | -300 | -214 | -150 | -100 | -51.67 | -45.79 | -33.74 | -49.42 | -13.98 |
| Capital Expenditures | -20.01 | -6.31 | -4.53 | -5.95 | -4.82 | -0.24 | -0.70 | -4.32 | -1.42 | -0.38 |
| Free Cash Flow | -270 | -306 | -218 | -156 | -105 | -51.91 | -46.49 | -38.07 | -50.84 | -14.37 |
| Cash & Equivalents | 453 | 504 | 359 | 330 | 214 | 152 | 82.00 | 99.12 | 55.70 | 107 |
| Total Debt | 210 | 322 | 164 | 154 | - | 14.35 | 14.47 | 0.70 | 1.04 | 2.34 |
| Net Cash / Debt | 243 | 182 | 194 | 176 | 214 | 137 | 67.53 | 98.43 | 54.66 | 105 |
| Assets | 850 | 790 | 627 | 1,037 | 908 | 210 | 128 | 110 | 69.80 | 113 |
| Liabilities | 374 | 447 | 274 | 677 | 561 | 87.79 | 81.81 | 40.87 | 40.20 | 47.62 |
| Book Value | 476 | 343 | 353 | 360 | 348 | 122 | 45.75 | 69.22 | 29.59 | 64.93 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Amicus Therapeutics, Inc. |
| Country |
United States |
| Employees |
584 |
| CEO |
John Francis Crowley |
Stock Information
| Ticker Symbol |
FOLD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FOLD |
| IPO Date |
May 31, 2007 |
Description
Amicus Therapeutics, a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.